Chairman Michael J. Farrell - 09 Nov 2026 Form 4 Insider Report for RESMED INC (RMD)

Reporting relationship: Chairman and CEO, Director
Issuer ticker: RMD
Reported as of: 09 Nov 2026
Net transaction value: -$1,175,089
SEC form: 4
Accepted by SEC: 12 Nov 2026, 06:04:15 UTC
Prior SEC filing: 08 Oct 2026
Next SEC filing: 13 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael J. Farrell, Chairman and CEO

Filing notes and source

Key filing fact

Chairman Michael J. Farrell filed Form 4 for RESMED INC (RMD) on 12 Nov 2026.

Key facts

This page summarizes Chairman Michael J. Farrell's Form 4 filing for RESMED INC (RMD).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Nov 2026, 06:04.

Change

Previous filing in this sequence was filed on 08 Oct 2026.
Current net transaction value: -$1,175,089.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001485164 Primary reporting owner

Farrell Michael J.

Relationship: Chairman and CEO, Director
Address: RESMED INC., 9001 SPECTRUM CENTER BLVD, SAN DIEGO
Signature: /s/ Michael J. Farrell, Chairman and CEO
Signature date: 10 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RMD transaction

ResMed Common Stock

Options Exercise

Transaction value
Shares: +683
Change %: +0.14%
Price: $146.34^*
Shares after: 480,486
Date: 09 Nov 2026
Ownership: Direct
Footnotes: F1

RMD transaction

ResMed Common Stock

Options Exercise

Transaction value
Shares: +4,310
Change %: +0.9%
Price: $146.34^*
Shares after: 484,796
Date: 09 Nov 2026
Ownership: Direct
Footnotes: F1

RMD transaction

ResMed Common Stock

Sale

Transaction value: -$1,175,089
Shares: -4,993
Change %: -1%
Price: $235.35
Shares after: 479,803
Date: 09 Nov 2026
Ownership: Direct
Footnotes: F1, F2

RMD holding

ResMed Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,090
Date: 09 Nov 2026
Ownership: Lisette and Michael Farrell Family Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RMD transaction Derivative

ResMed Common Stock Options

Options Exercise

Transaction value
Shares: -683
Change %: -14%
Price: $0.000000^*
Shares after: 4,310
Date: 09 Nov 2026
Ownership: Direct
Underlying class: ResMed Common Stock
Underlying amount: 683
Exercise price: $146.34
Footnotes: F1, F3

RMD transaction Derivative

ResMed Common Stock Options

Options Exercise

Transaction value
Shares: -4,310
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 09 Nov 2026
Ownership: Direct
Underlying class: ResMed Common Stock
Underlying amount: 4,310
Exercise price: $146.34
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price.

Footnote F3

Represents date options first become exercisable. Options vest 1/3 per year

Footnote F4

Represents date options first become exercisable. Options vest 1/3 per year